COLORECTAL CANCER THERAPEUTICS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025-2032)

Global colorectal cancer therapeutics market is estimated to be valued at USD 9.38 Bn in 2025 and is expected to exhibit a CAGR of 4.5% during the forecast period (2025-2032). Colorectal cancer is one of the most common cancers worldwide and a leading cause of cancer-related mortality. According to World Health Organization (WHO), in 2020, over 1.9 million new cases of colorectal cancer are diagnosed globally and more than 0.9 million deaths due to colorectal cancer occur annually. Rising prevalence of colorectal cancer and limited treatment options have boosted demand for effective therapeutics. Several biopharma companies are focusing on developing novel targeted therapeutic approaches such as targeted monoclonal antibodies, protein kinase inhibitors, and immune checkpoint inhibitors to treat colorectal cancer.

Market Dynamics

Global colorectal cancer therapeutics market growth is driven by rising prevalence of colorectal cancer worldwide. In 2020, according to the American Cancer Society, over 150,000 new cases of colorectal cancer are diagnosed in the U.S. every year. Moreover, increasing initiatives by governments and cancer organizations to spread awareness about early detection and treatment of colorectal cancer can drive the market growth. However, high costs associated with novel targeted therapies can hamper its widespread adoption. Ongoing research & development for developing new generation biomarker-guided personalized therapies can create lucrative growth opportunities.

Key features of the study

• This report provides in-depth analysis of the global colorectal cancer therapeutics market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global colorectal cancer therapeutics market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Sanofi, Bristol-Myers Squibb Company, Bayer AG, Ono Pharmaceutical Co. Ltd, ALX Oncology Inc., Daiichi Sankyo Company, Limited, Pfizer Inc., Exelixis, Inc., SOTIO Biotech AG, AB Science, BioNTech SE, Effector Therapeutics, Inc., and Treos Bio Limited
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global colorectal cancer therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global colorectal cancer therapeutics market

Market Segmentation

•  Therapy Type Insights (Revenue, USD, 2020 – 2032)
• • Chemotherapy
    • Alkylating Agents
    • Antimetabolites
    • Others
  • Immunotherapy
    • Immune Checkpoint Inhibitors
    • Oncolytic Virus Therapy
    • Others
  • Targeted Therapy
    • Monoclonal antibodies
    • Small molecule inhibitors
  • Others
•  Route of Administration Insights (Revenue, USD, 2020 – 2032)
• • Oral
  • Intravenous
  • Intramuscular
  • Subcutaneous
  • Others
•  Distribution Channel Insights (Revenue, USD, 2020 – 2032)
• • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Regional Insights (Revenue, USD, 2020 – 2032)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Sanofi
  • Bristol-Myers Squibb Company
  • Bayer AG
  • Ono Pharmaceutical Co. Ltd
  • ALX Oncology Inc.
  • Daiichi Sankyo Company, Limited
  • Pfizer Inc.
  • Exelixis, Inc.
  • SOTIO Biotech AG
  • AB Science
  • BioNTech SE
  • Effector Therapeutics, Inc.
  • Treos Bio Limited